Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
ORIGINAL

Predictive factors of COVID-19 in patients with negative RT-qPCR

J. López de la Iglesia a, T. Fernández-Villa b,∗, A. Rivero c, A. Carvajal d, E. Bay Simon e, M. Martínez Martínez f, H. Argüello d, H. Puente d, J.P. Fernández Vázquez g

a Especialista en Medicina Familiar y Comunitaria, Centro de salud Condesa, León, Spain
b Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS)/Instituto de Biomedicina (IBIOMED), Universidad de León, León, Spain
c Dirección de Enfermería, Gerencia de Atención Primaria del Área de Salud de León, Spain
d Departamento de Sanidad Animal, Universidad de León, León, Spain
e Residente de cuarto año de medicina familiar y comunitaria, Centro de Salud San Andrés del Rabanedo, León, Spain
f Enfermera de la Gerencia de Atención Primaria, León, Spain
g Gerencia de Atención Primaria de León, León, Spain

Received 22 May 2020; accepted 17 June 2020
Available online 23 June 2020

KEYWORDS
SARS-CoV-2;
RT-qPCR;
Diagnosis;
Fever;
Anosmia

Abstract
Objective: To evaluate the factors associated with false negatives in RT-qPCR in patients with mild-moderate symptoms of COVID-19.
Materials and methods: This was a cross-sectional study that used a random sample of non-hospitalized patients from the primary care management division of the Healthcare Area of Leon (58 RT-qPCR-positive cases and 52 RT-qPCR-negative cases). Information regarding symptoms was collected and all patients were simultaneously tested using two rapid diagnostic tests – RDTs (Combined – cRDT and Differentiated – dRDT). The association between symptoms and SARS-CoV-2 infection was evaluated by non-conditional logistic regression, with estimation of Odds Ratio.
Results: A total of 110 subjects were studied, 52% of whom were women (mean age: 48.2 ± 11.0 years). There were 42.3% of negative RT-qPCRs that were positive in some RDTs. Fever over 38 °C (present in 35.5% of cases) and anosmia (present in 41.8%) were the symptoms most associated with SARS-CoV-2 infection, a relationship that remained statistically significant in patients with negative RT-qPCR and some positive RDT (aOR = 6.64; 95%CI = 1.33–33.13 and aOR = 19.38; 95% CI = 3.69–101.89, respectively).
Conclusions: RT-qPCR is the technique of choice in the diagnosis of SARS-CoV-2 infection, but it is not exempt from false negatives. Our results show that patients who present mild or moderate

∗ Corresponding author.
E-mail address: tferv@unileon.es (T. Fernández-Villa).

https://doi.org/10.1016/j.semerg.2020.06.010
1138-3593/© 2020 Sociedad Española de Médicos de Atención Primaria (SEMergen). Published by Elsevier España, S.L.U. All rights reserved.
Introduction

One of the main strategies for the prevention and control of the COVID-19 pandemic is detecting and isolating the infection sources. The reverse transcription quantitative polymerase chain reaction (RT-qPCR) is the technique of choice for detecting infection sources due to its high sensitivity and specificity. It is also a well-known and widespread technique in the clinical laboratories of our hospitals. This method, however, is not free of false negatives, the most frequent causes of which being the inadequate sample collection, delays in transport, labeling errors and the poor virus elimination in the patient. For these reasons, in the face of clinical suspicion, a negative RT-qPCR result must be contrasted against other diagnostic tests.

The aim of this article is to understand the factors associated with false negatives in RT-qPCR in patients with mild-moderate symptoms of COVID-19.

Material and methods

Study design

A cross-sectional study was carried out. A random selection was made of 58 non-hospitalized patients with positive RT-qPCR and 52 negative RT-qPCR. Patients were selected from the register of confirmed or suspected COVID-19 cases from the primary care management of the Healthcare Area of Leon. More than 14 days had passed in all patients since the beginning of the symptoms.

Procedure

Participation in the study was voluntary. The invitation to participate in the study was extended via a telephone call, in which the participants were summoned for a biological sample and information collection. All protection regulations were followed during the collection process and the project was approved by the Ethics Committee of the Healthcare Area of Leon and the Bierzo (reference: 2073). After signing an informed consent, each participant completed a brief ad hoc questionnaire that collected information on socio-demographic data, symptoms, date of onset and end of symptoms and date of the RT-qPCR.

All patients were tested simultaneously with two RDTs:

- Combined (c-RDT) (one band): Wondfo® SARS-COV-2 Antibody test (Lateral Flow Method) of GUANGZHOU WONDFO BIOTECH CO LTD,
- Differentiated (d-RDT) (two bands): Allowing differentiation between IgG and IgM. All Test® 2019-nCoV IgG/IgM
Rapid Test Cassette of HANGZHOU ALL TEST BIOTECH CO LTD.

Both tests were performed by two nurses using a finger-stick whole blood sample. The first test jointly determines the presence of IgM and IgG, while the second test makes a differentiated measurement of both antibody subtypes. The results of the tests were read 10–15 min after they were carried out.

We considered as a case of COVID-19 those patients with a positive result to at least one of the RDTs or RT-qPCR.

**Statistical analysis**

Central and dispersion measures were calculated in quantitative variables (mean and standard deviation (SD)) and frequencies with their 95% confidence intervals in qualitative variables. Using non-conditional logistic regression models, adjusted by age and sex at minimum, we obtained the Odds Ratio (aOR) to be considered COVID-19 case, performing stratified analysis according to the results of the RDTs and the RT-qPCR. The characteristics of those patients with negative RT-qPCR and positive PDR were examined. All analyses were performed with the STATA 15 statistical package.9

**Results**

A total of 110 subjects were studied, of whom 51.8% were women. The age range was between 22 and 78 years, with a mean of 48.2 ± 11.0 years. The number of days from the onset of symptoms to the performance of the RDTs ranged from 14 to 40 days, with a median of 26 days.

Of the 110 patients, 80 (72.7%) had either RT-qPCR or a positive RDT for SARS-CoV-2 (20 were IgM positive, 64 were IgG positive, 64 were IgM or IgG positive, 46 were combined, 65 were RDT positive, and 58 were RT-qPCR positive). Of the 52 with negative RT-qPCR, 22 (42.3%) were positive for some RDT; there were 14 positives for the two RDTs and 8 only for RDTd. (Fig. 1)

Table 1 shows the distribution of symptoms and their association with being a COVID-19 case. A statistically significant association with fever, anosmia, ageusia, myalgia and anorexia were observed in the model adjusted for age and sex. Adjusting for age, sex and the signs and symptoms statistically associated with COVID-19, the significant association with anosmia (aOR = 20.39; 95%CI = 4.74–87.73) and fever (aOR = 4.33; 95%CI = 1.24–15.11) was maintained.

Fig. 2 shows that all the patients with fever and anosmia were positive in some test and in the case of patients with negative RT-qPCR but positive in some RDT, more than 80% (18/22) had either fever or anosmia or both. Table 2 shows how anosmia (aOR = 19.38) and the presence of fever (aOR = 6.64) are strongly and significantly associated with having COVID-19 in subjects who previously tested RT-qPCR-negative.

**Discussion**

The results of our study reflect that 42.3% of respondents with negative RT-qPCR were positive for some RDT. The symptoms most commonly associated with SARS-CoV-2 infection were fever over 38°C (present in 35.5% of cases) and anosmia (present in 41.8%), a relationship that remained significant in individuals with negative RT-qPCR and some positive RDT (aOR = 6.64; 95%CI = 1.33–33.13 and aOR = 19.38; 95% CI = 3.69–101.89 respectively).

RT-qPCR is the most widely used technique in the diagnosis of SARS-CoV-2 infection, given its high reliability.9 However, it is not exempt from false negatives, which may be due to tests with fewer genes detected, mild symptoms or very early stages of the disease, upper respiratory tract samples, denaturation of the materials used and/or delay in transport or processing of the sample.4,5

Our data show that 42.3% of the subjects analyzed were classified as healthy according to the technique of choice (RT-qPCR), presenting infection after the results obtained in the RDTs. The Spanish Society of Intensive and Critical Medicine and Coronary Units (SEMICYUC) warned that false negatives by RT-qPCR can reach 30% in hospitalized patients, referring to a study carried out by Yang et al. in China.5,9 These results highlight the need for caution in diagnosis, especially in cases of negative RT-qPCR and high clinical suspicion.

With regard to symptoms associated with SARS-CoV-2 infection, fever and anosmia were significant in the false negatives. These symptoms associated with the infection were not surprising, given that from the beginning of the pandemic, fever, cough and difficulty breathing were the warning symptoms. According to data published in a recent review, fever is present in 83–98% of cases, but up to 17% of patients may have afebrile illness.9 The Centers for Disease
Table 1  Risk of having at least one positive test according to different signs and symptoms.

| Signs or symptoms     | N  | n  | %   | aOR\(^a\) | 95% CI |
|-----------------------|----|----|-----|------------|--------|
| **Cough**             |    |    |     |            |        |
| No                    | 34 | 27 | 79.4| 1          |        |
| Yes                   | 76 | 53 | 69.7| 0.82       | 0.29   |
|                       |    |    |     |            | 2.30   |
| **Expectoration**     |    |    |     |            |        |
| No                    | 74 | 54 | 73.0| 1          |        |
| Yes                   | 35 | 25 | 71.4| 0.95       | 0.37   |
|                       |    |    |     |            | 2.42   |
| **Fever (<38 °C)**    |    |    |     |            |        |
| No                    | 39 | 27 | 69.2| 1          |        |
| Yes                   | 71 | 53 | 74.7| 1.47       | 0.59   |
|                       |    |    |     |            | 3.66   |
| **Fever (≥38 °C)**    |    |    |     |            |        |
| No                    | 71 | 46 | 64.8| 1          |        |
| Yes                   | 39 | 34 | 87.2| 4.14       | 1.35   |
|                       |    |    |     |            | 12.72  |
| **Shaking chills**    |    |    |     |            |        |
| No                    | 49 | 35 | 71.4| 1          |        |
| Yes                   | 61 | 45 | 73.8| 1.24       | 0.51   |
|                       |    |    |     |            | 3.02   |
| **Dyspnea**           |    |    |     |            |        |
| No                    | 64 | 46 | 71.9| 1          |        |
| Yes                   | 45 | 33 | 73.3| 1.94       | 0.73   |
|                       |    |    |     |            | 5.15   |
| **Chest pain**        |    |    |     |            |        |
| No                    | 71 | 54 | 76.1| 1          |        |
| Yes                   | 39 | 26 | 66.7| 0.83       | 0.33   |
|                       |    |    |     |            | 2.07   |
| **Headache**          |    |    |     |            |        |
| No                    | 45 | 32 | 71.1| 1          |        |
| Yes                   | 65 | 48 | 73.9| 1.75       | 0.68   |
|                       |    |    |     |            | 4.51   |
| **Nausea**            |    |    |     |            |        |
| No                    | 90 | 65 | 72.2| 1          |        |
| Yes                   | 20 | 15 | 75.0| 1.66       | 0.51   |
|                       |    |    |     |            | 5.41   |
| **Diarrhea**          |    |    |     |            |        |
| No                    | 62 | 42 | 67.7| 1          |        |
| Yes                   | 47 | 37 | 78.7| 2.34       | 0.90   |
|                       |    |    |     |            | 6.04   |
| **Anosmia**           |    |    |     |            |        |
| No                    | 64 | 37 | 57.8| 1          |        |
| Yes                   | 46 | 43 | 93.5| 19.75      | 4.76   |
|                       |    |    |     |            | 82.00  |
| **Ageusia**           |    |    |     |            |        |
| No                    | 59 | 34 | 57.6| 1          |        |
| Yes                   | 51 | 46 | 90.2| 9.92       | 3.09   |
|                       |    |    |     |            | 31.87  |
| **Sore throat**       |    |    |     |            |        |
| No                    | 73 | 54 | 74.0| 1          |        |
| Yes                   | 37 | 26 | 70.3| 1.00       | 0.40   |
|                       |    |    |     |            | 2.52   |
| **Asthenia**          |    |    |     |            |        |
| No                    | 28 | 18 | 64.3| 1          |        |
| Yes                   | 82 | 62 | 75.6| 2.00       | 0.74   |
|                       |    |    |     |            | 5.42   |
| **Myalgia**           |    |    |     |            |        |
| No                    | 53 | 35 | 66.0| 1          |        |
| Yes                   | 56 | 44 | 78.6| 2.63       | 1.02   |
|                       |    |    |     |            | 6.72   |
| **Anorexia**          |    |    |     |            |        |
| No                    | 69 | 46 | 66.7| 1          |        |
| Yes                   | 41 | 34 | 82.9| 3.28       | 1.17   |
|                       |    |    |     |            | 9.16   |

\(^a\) aOR: adjusted odds ratio by sex and age.
Control and Prevention (CDC) has expanded the list of symptoms associated with the disease to include chills, muscle pain, sore throat, and recent loss of taste or smell.\textsuperscript{10-12} This last symptom, anosmia, is emerging strongly among the cases detected worldwide, having been described by several studies with a prevalence between 33 and 86%\textsuperscript{13,14}. Despite not being present in all cases, these are very characteristic symptoms that can arise in the early stage of the disease and should be taken into account as a clinical suspicion.

The results obtained in this study must be interpreted with caution, given that the main limitations are the descriptive nature of the study and the small sample size. However, it is one of the first research studies in Spain to highlight the factors associated with false negatives in the test of choice in the diagnosis of COVID-19, to ensure the diagnosis of the disease.

### Conclusion

The rapid spread of the COVID-19 pandemic requires the swift generation of knowledge to combat this disease. Our results reflect how patients with fever and anosmia and negative RT-qPCR should be considered as suspected COVID-19 cases in clinical practice, given the percentage of false negatives that this test of choice is presenting. Furthermore, it highlights the need to perform a combination of tests, such as the use of RDTs, to ensure the diagnosis of the disease.

### Funding

This research has not received specific support from public sector agencies, the commercial sector or non-profit organizations.
Conflict of interest

The authors declare no conflict of interest.

Acknowledgements

The authors would like to thank all patients for their participation in this study who have voluntarily agreed to collaborate in the evaluation of diagnostic techniques against COVID-19. Thank you to the primary care management division of the Healthcare Area of Leon and the University of Leon also, because their collaboration has been crucial in developing this study.

References

1. Ministerio de Sanidad. Información científico - técnica. Enfermedad por coronavirus, covid-19. Available from: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/20200417ITCoronavirus.pdf [accessed 09.05.20].
2. Li C, Ren L. Recent progress on the diagnosis of 2019 Novel Coronavirus. Transbound Emerg Dis. 2020, http://dx.doi.org/10.1111/tbed.13620.
3. Ministerio de ciencia e Innovación. Nanociencia y Nanotecnología (ICN2), CSIC, CIBER-BBN y BIST Bellaterra, Barcelona (España). Técnicas y sistemas de diagnóstico para COVID-19. Available from: https://www.ciencia.gob.es/sttis/MICINN/Ministerio/FICHEROS/TecnicasDiagnosticoCOVID19-ICN2.pdf [accessed 10.05.20].
4. Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Recomendaciones institucionales. Documento de posicionamiento de la SEIMC sobre el diagnóstico microbiológico del COVID-19. Available from: https://seimc.org/contenidos/documentoscientificos/recomendaciones/seimc-rc-2020-PosicionamientoSEIMCdagnosticosmicrobiologicoCOVID19.pdf [accessed 17.05.20].
5. Madrigal-Rojas JP, Quesada-Loría M, García-Sánchez M, Solano-Chinchilla A. SARS CoV-2, manifestaciones clínicas y consideraciones en el abordaje diagnóstico de COVID-19. Revista Médica de Costa Rica. 2020;85.
6. Instituto de Salud Carlos III. Informe sobre estrategia de diagnóstico microbiológico del COVID-19 (Actualización) Madrid 19 de abril de 2020. Available from: https://www.semergen.es/files/docs/COVID-19/Documentos/Informe-lestrategia-microbiologico.pdf [accessed 10.05.20].
7. StataCorp. 2017. Stata: Release 15. Statistical Software. College Station, TX: StataCorp LLC.
8. Yang Y, Yang M, Shen C, Wang F, Yuan J, Li J, et al. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. MedRxiv. 2020, http://dx.doi.org/10.1101/2020.02.11.20021493.
9. Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC). Nota de prensa: Faltan estudios bien diseñados que apoyen la eficacia de los tratamientos antivirales y antiinflamatorios en la COVID-19. Available from: https://semicyuc.org/wp-content/uploads/2020/05/NdP-Seminario-Infecciosas.pdf [accessed 15.05.20].
10. Centros para el Control y la Prevención de Enfermedades – CDC. Síntomas de la enfermedad del coronavirus. Available from: https://espanol.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html [accessed 10.05.20].
11. Acter T, Uddin N, Das J, Akhter A, Choudhury TR, Kim S. Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency. Sci Total Environ. 2020;138996, http://dx.doi.org/10.1016/j.scitotenv.2020.138996.
12. Whitcroft KL, Hummel T. Olfactory dysfunction in COVID-19: diagnosis and management. JAMA. 2020, http://dx.doi.org/10.1001/jama.2020.8391.
13. Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, et al. Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: a cross-sectional study. CID. 2020;31, http://dx.doi.org/10.1093/cid/ciaa330.
14. Lechien J, Chiesa-Estomba C, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Oto-Rhino-Laryngol. 2020, http://dx.doi.org/10.1007/s00405-020-05965-1.